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Degradation of oxidized or oxidatively modiﬁed proteins is an essential part of the antioxidant defenses of cells. 4-Hydroxy-2-
nonenal, a major reactive aldehyde formed by lipid peroxidation, causes many types of cellular damage. It has been reported that
4-hydroxy-2-nonenal-modiﬁed proteins are degraded by the ubiquitin-proteasome pathway or, in some cases, by the lysosomal
pathway. However, our previous studies using U937 cells showedthat 4-hydroxy-2-nonenal-modiﬁed glyceraldehyde-3-phosphate
dehydrogenase is degraded by cathepsin G. In the present study, we isolated the 4-hydroxy-2-nonenal-modiﬁed glyceraldehyde-
3-phosphate dehydrogenase-degrading enzyme from rat neutrophils to an active protein fraction of 28kDa. Using the speciﬁc
antibody, the 28kDa protein was identiﬁed as cathepsin G. Moreover, the degradation activity was inhibited by cathepsin
G inhibitors. These results suggest that cathepsin G plays a crucial role in the degradation of 4-hydroxy-2-nonenal-modiﬁed
glyceraldehyde-3-phosphate dehydrogenase.
1.Introduction
Low-to-moderate concentrations of reactive oxygen species
aﬀect a great number of physiological functions. However,
when the reactive oxygen species concentration exceeds
the antioxidative capacity of an organism, animal cells
enter a state termed oxidative stress, in which the excess
reactive oxygen species induces oxidative damage on cellular
components. As a result, oxidative stress has been implicated
in a large range of diseases, including cancer, diabetes,
male infertility, autoimmune diseases, atherosclerosis, and
cardiovascular disorders [1–3].
Exposuretooxidativestress, whichoccursinthepresence
of reactive oxygen species and free radicals, causes many
adverse events including modiﬁcation of proteins and reac-
tions with DNA [4]. Lipid peroxidation also occurs, and
various reactive aldehydes, such as 2-alkenals, 4-hydroxy-2-
alkenals, and ketoaldehydes, are generated [5]. 4-Hydroxy-
2-nonenal (HNE) is a major reactive aldehyde formed by
the peroxidation of ω-6 polyunsaturated fatty acids, such
as linoleic acid and arachidonic acid [6], and is involved in
various physiological and pathological reactions [5, 6].
HNE has a high stability and reactivity and is largely
responsible for many types of cellular damage associated
with oxidative stress. HNE covalently binds to cysteine,
lysine, or histidine residues [5]. These adducts are detected
in several disease lesions, including in the brains of
patients with Alzheimer’s disease [7, 8] and in low-density
lipoproteins of atherosclerotic lesions [9]. HNE modiﬁes
enzymes and DNA and also aﬀects protein synthesis and
cell signaling [6, 10]. Many diverse enzymes are HNE
sensitive,suchasglyceraldehyde-3-phosphatedehydrogenase2 Oxidative Medicine and Cellular Longevity
(GAPDH) (EC 1.2.1.12) [11], glucose-6-phosphate dehy-
drogenase [12], glutathione reductase [13], interleukin-1β-
converting enzyme [14], and Na+,K +-ATPase [15].
The binding of HNE to proteins can cause conforma-
tional changes and amino acid modiﬁcations, as well as
the accumulation and aggregation of proteins which causes
cellular dysfunctions [16]. The breakdown of such modiﬁed
proteins is an essential defense mechanism against oxidative
stress in cells. The major proteolytic system for the degrada-
tion of oxidized or HNE-modiﬁed proteins is the ubiquitin-
proteasomepathway [17–19].Recently,ubiquitin-dependent
lysosomal degradation of HNE-modiﬁed proteins has been
reported in human lens epithelial cells [20].
GAPDH is a classical glycolytic enzyme which plays a
central role in energy production. Mammalian GAPDH dis-
plays a number of diverse activities unrelated to its gly-
colytic function. These include its role in membrane fusion,
microtubule bundling, phosphotransferase activity, nuclear
RNA export, DNA replication, and DNA repair. Moreover,
GAPDH is involved in apoptosis, age-related neurodegener-
ative diseases, prostate cancer, and viral pathogenesis [21].
Recentstudieshaveestablished severalnew rolesforGAPDH
including transcriptional control of histone gene expression,
recognition of fraudulently incorporated nucleotides in
DNA, and its mandatory participation in the maintenance
of telomere structure [22]. Furthermore, GAPDH plays an
apparent role in Alzheimer’s disease-related apoptotic cell
death [23].
In previous reports, we indicated that GAPDH modiﬁed
by HNE or by acetylleucine chloromethyl ketone, a synthetic
inhibitor of acylpeptide hydrolase, is degraded enzymatically
andisaccompaniedbythereleaseofa23kDafragmentinthe
U937 leukemia cell line [24, 25]. Furthermore, we puriﬁed
the HNE-modiﬁed GAPDH-degrading enzyme from a U937
cell extract and identiﬁed this enzyme as cathepsin G (EC
3.4.21.20) [26].
Neutrophils rapidly accumulate at sites of inﬂammation
and infection, and these cells are activated by bacterial and
host-derived factors. After phagocytosis of microorganisms
or other particulate substances, neutrophils secrete a variety
of mediators that possess potent proinﬂammatory and
antimicrobial activities. These mediators include a group
of antibiotic peptides and proteases that are stored in
neutrophil granules and released during the process of
degranulation. Human neutrophil elastase, proteinase 3, and
cathepsin G are three serine proteases of the chymotrypsin
family that are stored in the primary (azurophil) granules
of neutrophils. Neutrophils form the ﬁrst line of defense
during infection and are indispensable in this function.
However, imbalanced activity of neutrophil proteases may
contribute to disease. This imbalance may result from
insuﬃcient control of neutrophil proteases, as well as from
exposure to excessive protease activity due to the presence
of increased numbers of neutrophils in inﬂamed tissues.
Increased levels of neutrophil elastase are indeed associ-
a t e dw i t hv a r i o u si n ﬂ a m m a t o r yd i s o r d e r ss u c ha sc h r o n i c
obstructive pulmonary disease, genital tract inﬂammation,
and inﬂammatory bowel disease. Cystic ﬁbrosis, a disorder
characterized by a slow and relentless breakdown of the
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Figure 1: Concentration-dependent eﬀect of HNE on degradation
of GAPDH by incubation with cell extracts from neutrophils. The
cell extract from neutrophils was incubated with eGAPDH at the
indicated concentrationsofHNE at37◦Cfor3h. Reaction products
were separated on 12% SDS-PAGE gels and analyzed by Western
blotting using an anti-GAPDH mAb. Data are mean ± SE (bars)
values from four independent experiments. Signiﬁcant decreases in
GAPDH level compared to control are indicated by asterisks: ∗P<
0.05, ∗∗P<0.01, and ∗∗∗P<0.001.
normal airway architecture, emphasizes the important con-
tribution of neutrophil proteases to disease. Also, neutrophil
proteases are associated with systemic vasculitis, such as
Wegener’s granulomatosis. This type of vasculitis can aﬀect
multiple organs including the lungs and kidneys and is char-
acterized by granulomatous inﬂammation. Moreover, the
majority of the patients with granulomatous inﬂammation
also have circulating antineutrophil cytoplasmic autoanti-
bodies directed against proteinase 3. Several reports indicate
that such antibodies can activate neutrophils. Neutrophil
proteases are also associated with tumor development and
metastasis [27].
In the present study, we activated rat neutrophils with
N-formyl-Met-Leu-Phe (fMLF). We then examined whether
cathepsin G in the conditioned mediumfrom these activated
cells is eﬀective in HNE-modiﬁed GAPDH degradation.
2.Results
2.1. Degradation of HNE-Modiﬁed GAPDH by Incubation
with the Cell Extracts from Neutrophils. The dose-dependent
degradation of GAPDH by HNE was examined using the
cell extracts from neutrophils at concentrations from 10 to
100μM. As shown in Figure 1, the density of the band of
GAPDH decreased with increasing doses of HNE. The time-
dependent degradation of GAPDH by 100μMH N Ew a sa l s o
examined. The density of the band corresponding to the
36kDa band of GAPDH decreased over time. There was noOxidative Medicine and Cellular Longevity 3
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Figure 2: Time course of HNE-modiﬁed GAPDH degradation by
incubation with cell extracts from neutrophils. The cell extracts
from neutrophils were incubated with eGAPDH and 100μMH N E
(empty circle) or with eGAPDH alone without HNE as a control
(ﬁlled circle) at 37◦C for the indicated times. Reaction products
were separated on 12% SDS-PAGE gels and analyzed by Western
blotting using an anti-GAPDH mAb. Data are mean ± SE (bars)
values from four independent experiments. Signiﬁcant decreases
in GAPDH level compared to control are indicated by asterisks:
∗P<0.05 and ∗∗∗P<0.001.
decrease in the GAPDH level when the cell extracts from
neutrophils were incubated without HNE (Figure 2).
2.2. The Separation of the GAPDH-Degrading Enzyme.
Conditioned medium from rat neutrophils pretreated with
cytochalasin B and fMLF was concentrated by ammonium
sulfate precipitation and then fractionated on a Sephacryl S-
200 HR column. The elution proﬁle is shown in Figure 3.
Sincemyeloperoxidase, elastase, and cathepsin G are released
from neutrophils after stimulation with fMLF, activities of
these enzymes were determined. Myeloperoxidase activity
was detected at fractions 13–16 with the major protein
peak. Cathepsin G and GAPDH-degrading activity were well
separated from the major protein peak and coeluted in
the same fractions. The active fraction 25–28 was used for
further experiments.
The result of SDS-PAGE of the active protein fraction
isolated from the cell extracts from neutrophils is shown in
Figure 4(a). The single band in the gel was at the molecular
weight of 28kDa. To identify the 28kDa protein as cathepsin
G, we used an anticathepsin G antibody in Western blots
(Figure 4(b)).
2.3. Eﬀects of Cathepsin G Inhibitors on the HNE-Modiﬁed
GAPDH-Degrading Activity. The eﬀects of various cathep-
sin G inhibitors on the HNE-modiﬁed GAPDH-degrading
activity of the active fraction was investigated. The ser-
ine protease inhibitor DFP and cathepsin G inhibitors,
Z-GLF-CMK, cathepsin G inhibitor I, N-acetyl-eglin C,
and α1-antichymotrypsin, were used. The active fraction
was incubated with eGAPDH and HNE in the presence of
the respective inhibitors. All inhibitors eﬃciently inhibited
the HNE-modiﬁed GAPDH-degrading activity of the active
fraction (Figure 5).
3.Discussion
Neutrophils are the most abundant circulating leukocytes
in humans and play a fundamental role in the innate
immune response. This is best exempliﬁed by patients with
neutropenia, chronic granulomatous disease, or leukocyte
adhesion deﬁciency syndrome, who are particularly prone
to bacterial and fungal infections. Neutrophils are recruited
rapidly to sites of inﬂammation. Their primary role is to
kill invading bacteria and certain fungal species through
phagocytosis by the release of preformed granular enzymes
and proteins and by the production of a range of oxygen
species. However, the highly destructive capacity of these
cells also raises the potential for neutrophils to damage
healthy tissues which occurs in many inﬂammatory diseases
such as acute respiratory distress syndrome, inﬂammatory
bowel disease, and rheumatoid arthritis [28, 29].
HNE is an α,β-unsaturated aldehyde that is formed by
the peroxidation of ω-6 polyunsaturated fatty acids. HNE
is increased in hypercholesterolemia and in atherosclerotic
lesions causing accumulation of HNE-protein adducts [30].
Also, HNE promotes endothelial oxidative stress [10, 31],
endothelial barrier dysfunction [32, 33], and apoptosis [34,
35]. Recently, several publications report the role of HNE-
protein adducts in the pathogenesis and progression of
Alzheimer’s disease [36–38]. Since HNE-modiﬁed proteins
cause many cellular dysfunctions, the removal of HNE-
modiﬁed proteins causes important consequences for cell
survival. However, the degradation mechanisms of HNE-
modiﬁed proteins have not yet been clariﬁed. Previously, we
found that GAPDH degradation is triggered by HNE and 4-
hydroxy-2-hexenal and is catalyzed by an enzyme that diﬀers
from proteasomes and lysosomal enzymes [25]. Moreover,
we puriﬁed the HNE-modiﬁed GAPDH-degrading enzyme
from a U937 cell extract by dialysis and sequential chro-
matography and identiﬁed this enzyme as cathepsin G [26].
Cathepsin G is a major serine protease found in the
azurophil granules of neutrophils and monocytes and is
abundant in U937 cells. Cathepsin G has various functions,
includingplateletactivation,proteolysisofbloodcoagulation
factors, angiotensin II generation, chemotactic activity on
monocytes, and bactericidal activity. It is also involved in
the degradation of myosin, elastin, proteoglycan, laminin,
collagen, and immunoglobulins G and M [39, 40].
In the present study, we isolated an HNE-modiﬁed
GAPDH-degrading enzyme from cell extracts of rat neu-
trophils by dialysis and Sephacryl S-200 HR column chro-
matography (Figure 3). As a result, an active fraction con-
taining a 28kDa protein was identiﬁed as cathepsin G using
a cathepsin G-speciﬁc antibody (Figure 4). When the active4 Oxidative Medicine and Cellular Longevity
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Figure 3: The gel ﬁltration pattern of activity of the GAPDH-degrading enzyme in the cell extracts from neutrophils. The cell extracts
from neutrophils were fractionated by Sephacryl S-200 HR column chromatography equilibrated with 50mM sodium acetate buﬀer
containing 1M NaCl (pH 4.0). Activity of the GAPDH-degrading enzyme was assessed by the amount of the decreased GAPDH level,
which was analyzed by Western blotting using an anti-GAPDH mAb and digitized immunoblots. Myeloperoxidase activity was determined
spectrophotometrically. Elastase and cathepsin G activities were measured using ﬂuorometric substrates.
fraction was incubated with eGAPDH and HNE in the
presence of various cathepsin G inhibitors, the degradation
of GAPDH was strongly inhibited (Figure 5).
We observed that HNE-modiﬁed GAPDH was also
degraded in an extract of HL-60 cells, another human
myeloblastic leukemia cell line, but not in an extract of
Jurkat cells, a lymphoblastic leukemia cell line (data not
shown). Together with the high expression of cathepsin G in
neutrophils and monocytes, it is likely that the degradation
of HNE-modiﬁed proteins by cathepsin G occurs selectively
in granulocytes and monocyte cell types. It should be noted
thatthedegradationofHNE-modiﬁed GAPDHbycathepsin
G was independent of ubiquitin, whereas the degradation
of HNE-modiﬁed proteins by proteasomes and lysosomal
enzymes is dependent on ubiquitin[17, 18, 20].
Mechanisms responsible for removing proteins modiﬁed
by lipid peroxidation products are not well understood.
As a result, it is diﬃcult to delineate the contribution of
such a protein modiﬁcation to disease severity or progres-
sion. Previous studies report conﬂicting results. In lens
epithelial cells, HNE-modiﬁed proteins were preferentially
ubiquitinated and degraded by the lysosome with little or
no contribution by the proteasomal pathway of protein
degradation [20]. In the kidney of ferric nitrilotriacetate-
treated animals, proteasomal degradation was suggested
as the crucial pathway for the removal of protein-HNE
adducts [17]. A predominant role for the proteasome in the
removal of protein-HNE adducts is, however, inconsistent
with several studies showing that oxidative stress decreases
proteasome activity and that HNE inhibits the proteasome
by direct covalent modiﬁcation [17, 41]. In addition, in vitro
studies show that HNE-cross-linked proteins inhibit pro-
teasomal activity [42], suggesting that protein degradation
pathways other than the proteasome may be important for
theremovalofprotein-HNEadducts.Itislikelythatdiﬀerent
pathways of protein removal are engaged by diﬀerent cells
and that their contribution varies with the extent of lipid
peroxidation [43]( Figure 6).
In conclusion,thepresent study has clariﬁed that cathep-
sinGfromratneutrophilsdegradesHNE-modiﬁedGAPDH,
suggesting that cathepsin G plays an important role in
eliminating HNE-modiﬁedproteinsformedduringexposure
to oxidative stress.
4.Materialsand Methods
4.1. Chemicals. Human erythrocyte GAPDH (eGAPDH),
Z-Gly-Leu-Phe chloromethyl ketone (Z-GLF-CMK), N-ace-
tyl-eglin C, and α1-antichymotrypsin were obtained from
Sigma-Aldrich Co. (St. Louis, MO, USA). Diisopropyl ﬂu-
orophosphate (DFP), cytochalasin B, and fMLF were pur-
chased from Wako Pure Chemical Industries Ltd. (Osaka,
Japan). Succinyl-Ala-Ala-Pro-Phe-4-methylcoumaryl-7-am-
ide (Suc-AAPF-MCA)and N-methoxysuccinyl-Ala-Ala-Pro-
Val-4-methylcoumaryl-7-amide (Suc(OMe)-AAPV-MCA)
were obtained from the Peptide Institute (Osaka, Japan).
HNE was from Cayman Chemical Co. (Ann Arbor, Mich,
U S A ) .C a t h e p s i nGi n h i b i t o rIw a sf r o mC a l b i o c h e m( M e r c k
KGaA, Darmstadt, Germany). Sephacryl S-200 HR was from
GE Healthcare Life Sciences (Piscataway, NJ, USA). Other
chemicals and solvents were of analytical-reagent grade.Oxidative Medicine and Cellular Longevity 5
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Figure 4: SDS-PAGE analysis and Western blotting of the active
fraction separated from the cell extracts from neutrophils. The
active fraction separated from the cell extract from neutrophils was
analyzedby SDS-PAGEusing12%polyacrylamide gels.The protein
bands were analyzed by silver staining (a) and Western blotting
using an anticathepsin G pAb (b).
4.2. Antibodies. A mouse anti-GAPDH monoclonal anti-
body (mAb) was purchased from AbD Serotec (MorphoSys
AG, Martinsried, Germany). A rabbit anticathepsin G poly-
clonal antibody (pAb) was purchased from Calbiochem. A
biotinylated goat antimouse immunoglobulin pAb, biotiny-
lated goat antirabbit immunoglobulin pAb, and horseradish
peroxidase- (HRP-) conjugated streptavidin were obtained
from Dako Denmark A/S (Glostrup, Denmark).
4.3. Isolation of Neutrophils and Preparation of Cell Extracts
from Neutrophils. All animal experiments were carried out
in accordance with the 1980 Animal Experiment Guidelines
of the Japanese Government and have been approved by the
Animal Experiment Committee of our university. Retired
male Wistar rats were obtained from Sankyo Laboratory
(Tokyo, Japan) and were housed with free access to food
and water. A 12:12 light-dark cycle was maintained over 1
week. Neutrophils were isolated by polypeptone elicitation
as described previously [44] with a minor modiﬁcation.
In brief, 5mL of 10% polypeptone in sterile saline was
injected intraperitoneally. Twelve hours later, the rats were
anesthetized with diethyl ether and killed by decapitation.
The peritoneum containing the neutrophils was rinsed
with 30mL of phosphate-buﬀered saline (PBS) containing
1unit/mL of heparin. The rinsing solution was ﬁltered
through gauze and centrifuged for 7min at 500g. Red blood
cells were lysed in 15mL of 0.15M NH4Cl.
To preparethecell extract,neutrophils(2 × 108 cells/mL)
were collected, washed twice with ice-cold PBS, and treated
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Figure 5: Eﬀects of various cathepsin G inhibitors on the HNE-
modiﬁed GAPDH-degrading activity of the active fraction. The
active fraction separated from the cell extract from neutrophils was
incubated with eGAPDH and 100μMH N Ei nt h ep r e s e n c eo fD F P
or various cathepsin G inhibitors (Z-GLF-CMK: 100μM; cathepsin
G inhibitor I: 10μM; N-acetyl-eglin C: 1μM; α1-antichymotrypsin:
1μM; DFP: 1mM) at 37◦C for 3h. The reaction products were
separated by SDS-PAGE using 12% polyacrylamide gels and
analyzed by Western blotting using an anti-GAPDH mAb. Data
are mean ± SE (bars) values from four independent experiments.
Signiﬁcant decreases in GAPDH level compared to control are
indicated by asterisks: ∗∗∗P<0.001.
with cell lysis buﬀer (20mM phosphate buﬀer, pH 7.4,
1mM EDTA, 0.05% (v/v) Triton X-100) for 3min. The cell
lysate was centrifuged at 17,000g for 10min at 4◦C, and
the resultant supernatant (cell extract from neutrophils) was
used for further analysis. The protein concentration was
determinedbytheBradfordmethod[45]usingbovineserum
albumin as a reference standard.
4.4. Puriﬁcation Procedures for the HNE-Modiﬁed GAPDH-
Degrading Enzyme. Neutrophils isolated from 14 rats were
resuspended in Hanks’ solution (3 × 109 cells). Cytocha-
lasin B and fMLF were added at ﬁnal concentrations of
34.6μMa n d6 . 6μM, respectively. The cells were incubated
at 37◦C for 1h in a humidiﬁed atmosphere of 5% CO2
and 95% air and then centrifuged at 120g for 15min. The
resultant conditioned medium was collected and subjected
to ammonium sulfate (65% saturation) precipitation for
30min. The precipitate was collected by centrifugation at
15,000g for30min. The precipitatewas resuspended in4mL
of 50mM sodium acetate buﬀer containing 1M NaCl (pH
4.0) and dialyzed against the same buﬀer using a commonly
used dialysis tube (molecular weight cutoﬀ: 14,000). The
minor precipitatewas removedby centrifugation (8,000gfor
15min). The supernatant fraction after dialysis was applied6 Oxidative Medicine and Cellular Longevity
Protein A
Protein A
Protein B
Protein B
HNE
HNE HNE
HNE
HNE-modiﬁcation
Protein C
Protein C
Ubiquitin-proteasome
pathway
Degradation Degradation Degradation
Ubiquitin-dependent
lysosomal pathway
Cathepsin G
GAPDH
GAPDH
HNE-modiﬁcation
Figure 6: Mechanisms responsible for removing proteins modiﬁed
bylipidperoxidationproducts.Themajorproteolytic systemforthe
degradationofoxidized orHNE-modiﬁed proteins istheubiquitin-
proteasome pathway. Ubiquitin-dependent lysosomal degradation
of HNE-modiﬁed proteins also has been reported in human lens
epithelial cells. We observed that HNE-modiﬁed GAPDH was
degraded by cathepsin G in granulocytes and monocytes.
on a Sephacryl S-200 HR column (1.5 × 90cm) equilibrated
with the same buﬀe ra n de l u t e dw i t ht h es a m eb u ﬀer at
a ﬂow rate of 6mL/h. The UV absorbance of the eluate
was monitored at 280nm, and column fractions (3.0mL
per tube) were assayed for elastase, myeloperoxidase, and
cathepsin G activities.
4.5. Assay for the HNE-Modiﬁed GAPDH-Degrading Activity.
An aliquot of each fraction was incubated with eGAPDH
(6μg/mL) and 100μM HNEin 20mM phosphate buﬀer(pH
7.4) containing 1mM EDTA at 37◦Cf o r3 h .T om e a s u r e
the degradation activity in the cell extract from neutrophils,
an aliquot of the extract (0.4mg/mL) was incubated with
various concentrations of HNE at 37◦Ci nt h es a m eb u ﬀer.
The sample was then analyzed by Western blotting using the
anti-GAPDH mAb.
4.6. SDS-PAGE and Western Blotting. Protein samples were
prepared in SDS-PAGE sample buﬀer (62.5mM Tris-HCl,
pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v)
2-mercaptoethanol, and 0.01% (w/v) bromophenol blue).
Aliquots of the samples were subjected to SDS-PAGE
in 12% polyacrylamide gels according to the method of
Laemmli [46]. For silver staining, 12% polyacrylamide
gels were stained using a Wako Silver Stain II Kit (Wako
Pure Chemical Industries Ltd.). For Western blotting,
gels were electroblotted onto a polyvinylidene diﬂuoride
membrane (Immobilon-P Transfer Membrane; Millipore
Co.) at 180mA for 2h using a semidry transfer system
(Trans-Blot SD Cell; Bio-Rad Laboratories Inc., Hercules,
Calif, USA). The blotted membrane was blocked in 2%
Block Ace Solution (Dainippon Sumitomo Pharma Co.
Ltd., Osaka, Japan) for 1h, probed with the mouse anti-
GAPDH mAb (16ng/mL) or rabbit anticathepsin G pAb
(0.5μg/mL) for 2h, and then visualized using the biotiny-
lated antimouse or antirabbit immunoglobulins pAb, HRP-
streptavidin, and Immobilon Western Chemiluminescent
HRP Substrate (Millipore Co.). A LAS-1000 UV mini F85
LuminoimageAnalyzer(FujiﬁlmCo.,Tokyo,Japan)wasused
for chemiluminescence detection. The density of each band
wasquantiﬁedbyMultiGaugesoftware(Version3.0;Fujiﬁlm
Co.) and expressed in arbitrary units.
4.7. Assays for Enzyme Activities. Cathepsin G and elas-
tase activities were measured by known methods using
Suc-AAPF-MCA and Suc(OMe)-AAPV-MCA as substrates,
respectively [47, 48]. The ﬂuorescence intensity of the
solution was read at an emission wavelength of 460nm and
an excitation wavelength of 360nm. Activity of myeloper-
oxidase was determined spectrophotometrically (620nm)
using tetramethylbenzidine and H2O2 as substrates [49].
One unit of enzyme activity is deﬁned as the amount of
enzyme required for 1μm o lo ft h es u b s t r a t et ot u r ni n t ot h e
corresponding product in 1min at 37◦C.
4.8. Statistical Analysis. Data are represented as the mean ±
SE and analyzed by a two-tailed unpaired Student’s t-test.
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